收费全文 | 87754篇 |
免费 | 4417篇 |
国内免费 | 213篇 |
耳鼻咽喉 | 1136篇 |
儿科学 | 1906篇 |
妇产科学 | 1782篇 |
基础医学 | 11757篇 |
口腔科学 | 4012篇 |
临床医学 | 6656篇 |
内科学 | 21299篇 |
皮肤病学 | 1938篇 |
神经病学 | 7546篇 |
特种医学 | 2028篇 |
外科学 | 11630篇 |
综合类 | 388篇 |
一般理论 | 33篇 |
预防医学 | 7709篇 |
眼科学 | 1643篇 |
药学 | 5854篇 |
中国医学 | 365篇 |
肿瘤学 | 4702篇 |
2024年 | 56篇 |
2023年 | 537篇 |
2022年 | 462篇 |
2021年 | 1503篇 |
2020年 | 901篇 |
2019年 | 1500篇 |
2018年 | 2679篇 |
2017年 | 1676篇 |
2016年 | 1817篇 |
2015年 | 2452篇 |
2014年 | 2646篇 |
2013年 | 3607篇 |
2012年 | 7579篇 |
2011年 | 7946篇 |
2010年 | 3604篇 |
2009年 | 2685篇 |
2008年 | 6604篇 |
2007年 | 6818篇 |
2006年 | 6701篇 |
2005年 | 6424篇 |
2004年 | 5796篇 |
2003年 | 5266篇 |
2002年 | 4972篇 |
2001年 | 1653篇 |
2000年 | 2145篇 |
1999年 | 1084篇 |
1998年 | 295篇 |
1997年 | 221篇 |
1996年 | 220篇 |
1995年 | 201篇 |
1994年 | 157篇 |
1993年 | 156篇 |
1992年 | 162篇 |
1991年 | 146篇 |
1990年 | 91篇 |
1989年 | 107篇 |
1988年 | 68篇 |
1987年 | 67篇 |
1986年 | 81篇 |
1985年 | 96篇 |
1984年 | 121篇 |
1983年 | 83篇 |
1982年 | 103篇 |
1981年 | 85篇 |
1980年 | 94篇 |
1979年 | 49篇 |
1978年 | 50篇 |
1977年 | 47篇 |
1976年 | 43篇 |
1974年 | 46篇 |
Design and methods: Sixty patients with clinical and mycological diagnosis of PV were randomly assigned to receive either 1 g dapaconazole tosylate 2% cream or 1 g ketoconazole 2% cream. Treatments were applied once a day for 28 days. A dermatologist evaluated efficacy and safety daily, and weekly laboratorial tests were performed. The primary end point was a clinical and mycological cure of lesions after 28 days of treatment. The secondary end point was the time to clinical healing assessed by Kaplan–Meier analysis and Log-rank testing.
Results: Fifty-three patients adhered to protocol rules. Clinical and mycological cure was achieved in 84.6% (22/26) and 92.6% (25/27) of patients treated with ketoconazole and dapaconazole, respectively (difference [effect size] = 8.0%, Standard error of difference: 8.69%, 95% CI: –6.3 to 22.3%). Median time to healing was 23.5 and 21 days for ketoconazole and dapaconazole, respectively (p = 0.126). Adverse events occurred only in ketoconazole-treated patients (13%; 4/30).
Conclusion: Dapaconazole tosylate is non-inferior to ketoconazole when used at a dose of 20 mg/day for 28 consecutive days for the treatment of PV. Dapaconazole also demonstrated a good safety profile. 相似文献
Area covered: The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-α (etanercept, infliximab, adalimumab), IL-1β (anakinra, canakinumab) and IL-6 (tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists.
Expert opinion: The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity. 相似文献
Areas covered: The use of lamivudine (LAM) as the only active anti-HBV agent should strongly be discouraged in HIV-HBV coinfected patients, although it might be considered for individuals with low serum HBV-DNA and in the absence of liver cirrhosis as an exception. In any other case drug resistance may cause any clinical benefit of this antiviral HBV therapy to disappear, and lead to cross-resistance with other antivirals and even occasionally select for HBV vaccine escape mutants. In cirrhotics, liver enzyme flares may be accompanied by life-threatening decompensation. Entecavir is generally not recommended as an anti-HBV agent in HIV-HBV coinfected patients given its low residual antiretroviral activity and potential for selection of resistance mutations in HIV. Adefovir is not active against HIV using HBV dosing and is no longer recommended as HBV therapy given its limited antiviral effect. Finally, telbivudine is not active against HIV, it is less potent than TDF against HBV and depicts low barrier to resistance and cross-resistance to LAM or emtricitabine.
Expert Opinion: The introduction of TDF has drastically reduced the clinical relevance of hepatitis B drug resistance in HIV-HBV coinfected individuals. The use of LAM as the only active anti-HBV agent should strongly be discouraged in this population. 相似文献